2.	REVISIONS OF PREVIOUSLY-ISSUED FINANCIAL STATEMENTS

During the financial close for fiscal year 2018 the Company determined that it had not fully and timely taken into account changes in the business environment and experience with ultimate collection from third-party payors in estimating the amount of revenue that could be judged fixed or determinable at the date of performance of tests during 2018 and in previous annual and quarterly periods, and consequently, certain immaterial errors existed in previously reported amounts of revenue. However, the Company concluded that the cumulative effect of correcting the errors in 2018 would materially misstate the Company’s Consolidated Financial Statements for the year ended June 30, 2018. Accordingly, the accompanying prior period results have been revised to reflect the correction of these immaterial errors in each period.

The following tables presents the revised results for each previously reported period, the adjustments made to each period and the previously reported amounts to summarize the effect of the corrections on the previously reported consolidated financial statements for the periods presented.

	Year ended June 30,
	2017
	(As Reported)			(Adjustment)			(Restated)
ASSETS
Current assets:
Cash and cash equivalents	$	102.4		$	-		$	102.4
Marketable investment securities		48.3			-			48.3
Prepaid expenses		12.7			-			12.7
Inventory		42.2			-			42.2
Trade accounts receivable, less allowance for doubtful accounts of $7.6 in 2017		105.6			(15.4	)		90.2
Prepaid taxes		0.2			-			0.2
Other receivables		5.7			-			5.7
Total current assets		317.1			(15.4	)		301.7
Property, plant and equipment, net		51.1			-			51.1
Long-term marketable investment securities		48.5			-			48.5
Intangibles, net		491.6			(0.1	)		491.5
Goodwill		316.1			-			316.1
Total assets	$	1,224.4		$	(15.5	)	$	1,208.9
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	22.0		$	-		$	22.0
Accrued liabilities		65.6			-			65.6
Short-term contingent consideration		127.3			-			127.3
Deferred revenue		2.6			-			2.6
Total current liabilities		217.5			-			217.5
Unrecognized tax benefits		25.2			-			25.2
Other long-term liabilities		7.2			-			7.2
Contingent consideration		13.2			-			13.2
Long-term debt		99.1			-			99.1
Long-term deferred taxes		84.4			(5.7	)		78.7
Total liabilities		446.6			(5.7	)		440.9
Commitments and contingencies
Stockholders’ equity:
Common stock, 68.4 shares outstanding at June 30, 2017		0.7			-			0.7
Additional paid-in capital		851.4			-			851.4
Accumulated other comprehensive loss		(5.5	)		-			(5.5	)
Accumulated deficit		(68.4	)		(9.8	)		(78.2	)
Total Myriad Genetics, Inc. stockholders' equity		778.2			(9.8	)		768.4
Non-controlling interest		(0.4	)		-			(0.4	)
Total stockholders' equity		777.8			(9.8	)		768.0
Total liabilities and stockholders’ equity	$	1,224.4		$	(15.5	)	$	1,208.9

In millions, except per share amounts	Year Ended June 30,
	2017
	(As Reported)			(Adjustment)			(Restated)
Molecular diagnostic testing	$	722.1		$	(1.5	)	$	720.6
Pharmaceutical and clinical services		49.3			-			49.3
Total revenue		771.4			(1.5	)		769.9
Costs and expenses:
Cost of molecular diagnostic testing		145.2			-			145.2
Cost of pharmaceutical and clinical services		26.0			-			26.0
Research and development expense		74.4			-			74.4
Change in the fair value of contingent consideration		(0.8	)		-			(0.8	)
Selling, general, and administrative expense		476.4			-			476.4
Total costs and expenses		721.2			-			721.2
Operating income		50.2			(1.5	)		48.7
Other income (expense):
Interest income		1.2			-			1.2
Interest expense		(6.0	)		-			(6.0	)
Other		(2.5	)		(0.5	)		(3.0	)
Total other income (expense):		(7.3	)		(0.5	)		(7.8	)
Income before income tax		42.9			(2.0	)		40.9
Income tax provision		21.3			(0.7	)		20.6
Net income		21.6			(1.3	)		20.3
Net loss attributable to non-controlling interest		(0.2	)		-			(0.2	)
Net income attributable to Myriad Genetics, Inc. stockholders	$	21.8		$	(1.3	)	$	20.5
Earnings per share:
Basic	$	0.32		$	(0.02	)	$	0.30
Diluted	$	0.32		$	(0.02	)	$	0.30
Weighted average shares outstanding:
Basic		68.3			68.3			68.3
Diluted		68.8			68.8			68.8

In millions, except per share amounts	Year Ended June 30,
	2016
	(As Reported)			(Adjustment)			(Restated)
Molecular diagnostic testing	$	705.7		$	(13.3	)	$	692.4
Pharmaceutical and clinical services		48.1			-			48.1
Total revenue		753.8			(13.3	)		740.5
Costs and expenses:
Cost of molecular diagnostic testing		132.8			-			132.8
Cost of pharmaceutical and clinical services		24.5			-			24.5
Research and development expense		70.6			-			70.6
Change in the fair value of contingent consideration		-			-			-
Selling, general, and administrative expense		359.1			0.1			359.2
Total costs and expenses		587.0			0.1			587.1
Operating income		166.8			(13.4	)		153.4
Other income (expense):
Interest income		0.9			-			0.9
Interest expense		(0.3	)		-			(0.3	)
Other		1.5			0.5			2.0
Total other income (expense):		2.1			0.5			2.6
Income before income tax		168.9			(12.9	)		156.0
Income tax provision		43.6			(4.8	)		38.8
Net income		125.3			(8.1	)		117.2
Net loss attributable to non-controlling interest		-			-			-
Net income attributable to Myriad Genetics, Inc. stockholders	$	125.3		$	(8.1	)	$	117.2
Earnings per share:
Basic	$	1.79		$	(0.12	)	$	1.67
Diluted	$	1.71		$	(0.11	)	$	1.60
Weighted average shares outstanding:
Basic		70.0			70.0			70.0
Diluted		73.4			73.4			73.4

In millions, except per share amounts	Year Ended June 30,
	2015
	(As Reported)			(Adjustment)			(Restated)
Molecular diagnostic testing	$	695.5		$	(0.6	)	$	694.9
Pharmaceutical and clinical services		27.6			-			27.6
Total revenue		723.1			(0.6	)		722.5
Costs and expenses:
Cost of molecular diagnostic testing		132.8			-			132.8
Cost of pharmaceutical and clinical services		14.6			-			14.6
Research and development expense		75.5			-			75.5
Change in the fair value of contingent consideration		-			-			-
Selling, general, and administrative expense		366.0			-			366.0
Total costs and expenses		588.9			-			588.9
Operating income		134.2			(0.6	)		133.6
Other income (expense):
Interest income		0.4			-			0.4
Interest expense		(0.2	)		-			(0.2	)
Other		0.5			-			0.5
Total other income (expense):		0.7			-			0.7
Income before income tax		134.9			(0.6	)		134.3
Income tax provision		54.7			(0.2	)		54.5
Net income		80.2			(0.4	)		79.8
Net loss attributable to non-controlling interest		-			-			-
Net income attributable to Myriad Genetics, Inc. stockholders	$	80.2		$	(0.4	)	$	79.8
Earnings per share:
Basic	$	1.12		$	(0.01	)	$	1.12
Diluted	$	1.08		$	(0.01	)	$	1.07
Weighted average shares outstanding:
Basic		71.3			71.3			71.3
Diluted		74.5			74.5			74.5

In millions, except per share amounts	Quarters Ended
Unaudited	Mar 31,			Dec 31,			Sep 30,
	2018			2017			2017
Consolidated Statement of Operations Data:	(Restated)			(Restated)			(Restated)
Molecular diagnostic testing	$	177.3		$	177.9		$	176.5
Pharmaceutical and clinical services		13.8			14.8			11.4
Total Revenue		191.1			192.7			187.9
Costs and expenses:
Cost of molecular diagnostic testing		36.8			37.7			36.2
Cost of pharmaceutical and clinical services		7.3			6.7			6.8
Research and development expense		18.5			16.8			17.8
Change in the fair value of contingent consideration		(1.2	)		13.0			(73.2	)
Selling, general and administrative expense		115.1			115.4			115.2
Total costs and expenses		176.5			189.6			102.8
Operating income		14.6			3.1			85.1
Other income (expense):
Interest income		0.5			0.4			0.4
Interest expense		(0.5	)		(0.7	)		(0.9	)
Other		(0.5	)		(0.4	)		(0.3	)
Total other income (expense)		(0.5	)		(0.7	)		(0.8	)
Income before income taxes		14.1			2.4			84.3
Income tax provision		4.5			(26.3	)		4.8
Net income		9.6			28.7			79.5
Net loss attributable to non-controlling interest		(0.1	)		-			(0.1	)
Net income attributable to Myriad Genetics, Inc. stockholders	$	9.7		$	28.7		$	79.6
Earnings per share:
Basic	$	0.14		$	0.41		$	1.16
Diluted	$	0.13		$	0.40		$	1.13
Weighted average shares outstanding:
Basic		69.8			69.3			68.6
Diluted		72.4			71.9			70.4

In millions, except per share amounts	Quarters Ended
Unaudited	Mar 31,			Dec 31,			Sep 30,
	2018			2017			2017
Consolidated Statement of Operations Data:	(adjustments)			(adjustments)			(adjustments)
Molecular diagnostic testing	$	(2.4	)	$	(1.3	)	$	(2.3	)
Pharmaceutical and clinical services		-			-			-
Total Revenue		(2.4	)		(1.3	)		(2.3	)
Costs and expenses:
Cost of molecular diagnostic testing		-			-			-
Cost of pharmaceutical and clinical services		-			-			-
Research and development expense		-			-			-
Change in the fair value of contingent consideration		-			-			-
Selling, general and administrative expense		-			-			-
Total costs and expenses		-			-			-
Operating income		(2.4	)		(1.3	)		(2.3	)
Other income (expense):
Interest income		-			-			-
Interest expense		-			-			-
Other		-			-			-
Total other income (expense)		-			-			-
Income before income taxes		(2.4	)		(1.3	)		(2.3	)
Income tax provision		(0.7	)		2.1			(0.8	)
Net income		(1.7	)		(3.4	)		(1.5	)
Net loss attributable to non-controlling interest		-			-			-
Net income attributable to Myriad Genetics, Inc. stockholders	$	(1.7	)	$	(3.4	)	$	(1.5	)
Earnings per share:
Basic	$	(0.02	)	$	(0.05	)	$	(0.02	)
Diluted	$	(0.02	)	$	(0.05	)	$	(0.02	)
Weighted average shares outstanding:
Basic		69.8			69.3			68.6
Diluted		72.4			71.9			70.4

In millions, except per share amounts	Quarters Ended
Unaudited	Mar 31,			Dec 31,			Sep 30,
	2018			2017			2017
Consolidated Statement of Operations Data:	(As Reported)			(As Reported)			(As Reported)
Molecular diagnostic testing	$	179.7		$	179.2		$	178.8
Pharmaceutical and clinical services		13.8			14.8			11.4
Total Revenue		193.5			194.0			190.2
Costs and expenses:
Cost of molecular diagnostic testing		36.8			37.7			36.2
Cost of pharmaceutical and clinical services		7.3			6.7			6.8
Research and development expense		18.5			16.8			17.8
Change in the fair value of contingent consideration		(1.2	)		13.0			(73.2	)
Selling, general and administrative expense		115.1			115.4			115.2
Total costs and expenses		176.5			189.6			102.8
Operating income		17.0			4.4			87.4
Other income (expense):
Interest income		0.5			0.4			0.4
Interest expense		(0.5	)		(0.7	)		(0.9	)
Other		(0.5	)		(0.4	)		(0.3	)
Total other income (expense)		(0.5	)		(0.7	)		(0.8	)
Income before income taxes		16.5			3.7			86.6
Income tax provision		5.2			(28.4	)		5.6
Net income		11.3			32.1			81.0
Net loss attributable to non-controlling interest		(0.1	)		-			(0.1	)
Net income attributable to Myriad Genetics, Inc. stockholders	$	11.4		$	32.1		$	81.1
Earnings per share:
Basic	$	0.16		$	0.46		$	1.18
Diluted	$	0.16		$	0.45		$	1.15
Weighted average shares outstanding:
Basic		69.8			69.3			68.6
Diluted		72.4			71.9			70.4

In millions, except per share amounts	Quarters Ended
Unaudited	Jun 30,			Mar 31,			Dec 31,			Sep 30,
	2017			2017			2016			2016
Consolidated Statement of Operations Data:	(Restated)			(Restated)			(Restated)			(Restated)
Molecular diagnostic testing	$	187.0		$	183.0		$	184.1		$	166.5
Pharmaceutical and clinical services		12.6			11.7			12.6			12.4
Total Revenue		199.6			194.7			196.7			178.9
Costs and expenses:
Cost of molecular diagnostic testing		35.6			37.9			37.4			34.3
Cost of pharmaceutical and clinical services		6.9			6.4			7.0			5.7
Research and development expense		18.8			17.6			18.6			19.4
Change in the fair value of contingent consideration		(2.7	)		5.2			(3.8	)		0.5
Selling, general and administrative expense		122.1			122.1			120.3			111.9
Total costs and expenses		180.7			189.2			179.5			171.8
Operating income		18.9			5.5			17.2			7.1
Other income (expense):
Interest income		0.3			0.3			0.3			0.3
Interest expense		(1.2	)		(1.5	)		(2.6	)		(0.7	)
Other		(0.1	)		1.5			(2.6	)		(1.8	)
Total other income (expense)		(1.0	)		0.3			(4.9	)		(2.2	)
Income before income taxes		17.9			5.8			12.3			4.9
Income tax provision		5.8			3.0			6.2			5.6
Net income		12.1			2.8			6.1			(0.7	)
Net loss attributable to non-controlling interest		(0.2	)		-			-			-
Net income attributable to Myriad Genetics, Inc. stockholders	$	12.3		$	2.8		$	6.1		$	(0.7	)
Earnings per share:
Basic	$	0.18		$	0.04		$	0.09		$	(0.01	)
Diluted	$	0.18		$	0.04		$	0.09		$	(0.01	)
Weighted average shares outstanding:
Basic		68.2			68.1			68.2			68.8
Diluted		68.9			68.3			68.3			68.8

In millions, except per share amounts	Quarters Ended
Unaudited	Jun 30,			Mar 31,			Dec 31,		Sep 30,
	2017			2017			2016		2016
Consolidated Statement of Operations Data:	(adjustments)			(adjustments)			(adjustments)		(adjustments)
Molecular diagnostic testing	$	(0.9	)	$	(2.2	)	$	0.2	$	1.4
Pharmaceutical and clinical services		-			-			-		-
Total Revenue		(0.9	)		(2.2	)		0.2		1.4
Costs and expenses:
Cost of molecular diagnostic testing		-			-			-		-
Cost of pharmaceutical and clinical services		-			-			-		-
Research and development expense		-			-			-		-
Change in the fair value of contingent consideration		-			-			-		-
Selling, general and administrative expense		-			-			-		-
Total costs and expenses		-			-			-		-
Operating income		(0.9	)		(2.2	)		0.2		1.4
Other income (expense):
Interest income		-			-			-		-
Interest expense		-			-			-		-
Other		-			-			-		(0.5	)
Total other income (expense)		-			-			-		(0.5	)
Income before income taxes		(0.9	)		(2.2	)		0.2		0.9
Income tax provision		(0.3	)		(0.8	)		-		0.4
Net income		(0.6	)		(1.4	)		0.2		0.5
Net loss attributable to non-controlling interest		-			-			-		-
Net income attributable to Myriad Genetics, Inc. stockholders	$	(0.6	)	$	(1.4	)	$	0.2	$	0.5
Earnings per share:
Basic	$	(0.01	)	$	(0.02	)	$	0.00	$	0.01
Diluted	$	(0.01	)	$	(0.02	)	$	0.00	$	0.01
Weighted average shares outstanding:
Basic		68.2			68.1			68.2		68.8
Diluted		68.9			68.3			68.3		68.8


In millions, except per share amounts	Quarters Ended
Unaudited	Jun 30,			Mar 31,			Dec 31,			Sep 30,
	2017			2017			2016			2016
Consolidated Statement of Operations Data:	(As Reported)			(As Reported)			(As Reported)			(As Reported)
Molecular diagnostic testing	$	187.9		$	185.2		$	183.9		$	165.1
Pharmaceutical and clinical services		12.6			11.7			12.6			12.4
Total Revenue		200.5			196.9			196.5			177.5
Costs and expenses:
Cost of molecular diagnostic testing		35.6			37.9			37.4			34.3
Cost of pharmaceutical and clinical services		6.9			6.4			7.0			5.7
Research and development expense		18.8			17.6			18.6			19.4
Change in the fair value of contingent consideration		(2.7	)		5.2			(3.8	)		0.5
Selling, general and administrative expense		122.1			122.1			120.3			111.9
Total costs and expenses		180.7			189.2			179.5			171.8
Operating income		19.8			7.7			17.0			5.7
Other income (expense):
Interest income		0.3			0.3			0.3			0.3
Interest expense		(1.2	)		(1.5	)		(2.6	)		(0.7	)
Other		(0.1	)		1.5			(2.6	)		(1.3	)
Total other income (expense)		(1.0	)		0.3			(4.9	)		(1.7	)
Income before income taxes		18.8			8.0			12.1			4.0
Income tax provision		6.1			3.8			6.2			5.2
Net income		12.7			4.2			5.9			(1.2	)
Net loss attributable to non-controlling interest		(0.2	)		-			-			-
Net income attributable to Myriad Genetics, Inc. stockholders	$	12.9		$	4.2		$	5.9		$	(1.2	)
Earnings per share:
Basic	$	0.19		$	0.06		$	0.09		$	(0.02	)
Diluted	$	0.19		$	0.06		$	0.09		$	(0.02	)
Weighted average shares outstanding:
Basic		68.2			68.1			68.2			68.8
Diluted		68.9			68.3			68.3			68.8